October 24, 2026
Although medications such as Mounjaro and Zepbound have shown efficacy in helping individuals lose weight, there are not yet enough
The company also announced that it has submitted its new glucose monitoring system to the FDA for approval.
While the industry as a whole still faces challenges, there are positive trends appearing for pharmaceutical and medical device companies.
Best practices for defending against lawsuits based on pharmaceutical labeling, including avenues for early resolution of the case and, as
SH-105 eliminates the need for powder reconstitution, which Shorla stated will bolster the novel product’s efficiency and lower the risks
Both companies are now under the Norstella umbrella. Evaluate announced the acquisition of J+D Forecasting, a provider of forecasting solutions
Merck has acquired Harpoon Therapeutics with its clinical stage T-cell engager, whereas Johnson & Johnson acquired Ambrx Biopharma with its
Merck is actively enrolling patients across Phase III trials for four novel candidates for hematologic malignancies and solid tumors. Merck’s
Proposed acquisition would have given IQVIA a market-leading position in healthcare advertising. Following a review spanning November and December 2023,
Trial data show 89Zr-DFO-girentuximab was more effective than traditional PET/CT imaging in identifying malignant renal cell carcinoma lesions. Telix Pharmaceuticals
JAMA study investigates whether physical or behavioral healthcare needs are associated with the risk of underinsurance across household income levels.
Cretostimogene grenadenorepvec (CG0070) is currently being evaluated for the treatment of patients with high-risk Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer
Over the past 15 years, on average, racial and ethnic diversity in multiple US regions has increased by 1% to
VYD222 is a broadly neutralizing, half-life extended monoclonal antibody developed specifically to prevent COVID-19 in immunocompromised adults and adolescents. Invivyd,
Merger agreement includes the Gracell FasTCAR platform, which could significantly improve the efficacy of CAR T-cell therapies. AstraZeneca had a
Practical recommendations for a path forward for both biopharma C-Suites and their employees. Kerry McKittrick is a co-director of the
Artificial intelligence (AI) has enormous potential in healthcare, but all too often, it gets misunderstood. Especially with the proliferation of
Pharm Exec spent the year speaking with some of the most interesting professionals from the life sciences industry.
Zoryve (roflumilast) topical foam, 0.3% is the first approved treatment for seborrheic dermatitis with a new mechanism of action in
As companies continued to expand their DE&I efforts, Pharm Exec was there to cover it in 2023. Equity for Women
Pharma marketing teams had to deal with big changes in 2023. Q&A With UCB’s Camille Lee on New Psoriasis Medication
Published on: December 27, 2023 Our top five episodes of the year. The Explosive Arrival of Chat GPT and Generative AIFran
As this exciting technology exploded in 2023, Pharm Exec was there to cover it all. The Promise and Challenges of
Five trends in pharmaceutical marketing from the past year. Doctors as influencers A recent Hootsuite social trends presentation focused on
Jemperli plus standard-of-care chemotherapy with carboplatin and paclitaxel, followed by Jemperli plus Zejula as maintenance therapy produced a statistically significant
Enabling Authenticity Natalie Bickford, chief people officer at Sanofi, reveals how she approaches the employee experience, which ultimately influences employee
Pivotal trial findings show favorable clinical safety and efficacy data for mRNA-1345 in lowering the incidence of respiratory syncytial virus-associated
Indication of Adbry (tralokinumab-ldrm) expanded to include patients 12 to 17 years of age with moderate-to-severe atopic dermatitis whose disease
Filsuvez (birch triterpenes) is indicated to treat partial thickness wounds associated with junctional epidermolysis bullosa and dystrophic epidermolysis bullosa. The
Garadacimab is a novel, first-in-class, recombinant monoclonal antibody for hereditary angioedema that targets activated Factor XII. The FDA has accepted
Published on: December 21, 2023 Explore the implementation of enterprise laboratory software and the start of a digital transformation in your
In a recent article published by Oxford Academic, authors discussed a number of ways that artificial intelligence (AI) and machine
Published on: December 21, 2023 Explore the implementation of enterprise laboratory software and the start of a digital transformation in your
American Heart Association survey suggests holiday stress has a major impact on health habits. A recent survey released by the
Data will continue to grow in importance in 2024. Many of the biggest stories in 2023 were related to technological
If approved by the FDA, Xolair would be the first drug indicated to lower allergic reactions to multiple foods after
Merck’s Biologics License Application for V116, a novel 21-valent pneumococcal conjugate vaccine has been given a Prescription Drug User Fee
JAMA study aims to discover whether ignoring medical advice relates to financial status among patients with heart failure. Recently published
In the coming year, efficiency and automation will take center stage to maximize constrained resources but balancing sensible financial management
Drug companies face new hurdles in a rapidly changing marketplace. How do they finance new drug development amid the uncertainty?
Welireg (belzutifan) approved for the treatment of adults with advanced renal cell carcinoma that progressed after a regimen of a
Adjuvant treatment with Moderna’s mRNA-4157 (V940) in combination with Merck’s Keytruda lowered the risk of recurrence or death by 49%
The importance of enabling customer intelligence at scale. Most healthcare professionals (91%) place a high value on scientific exchange1 with
Erasca will initiate the pivotal SEACRAFT-2 trial in the first half of 2024 to evaluate naporafenib in combination with trametinib
In clinical trials, Padcev (enfortumab vedotin-ejfv) plus Keytruda (pembrolizumab) produced a statistically significant improvement in survival compared to platinum-based chemotherapy
CDC data show hospitalizations among all age groups spiked by 200% for influenza, 51% for COVID-19, and 60% for respiratory
JAMA Network study evaluates current attitudes toward individuals with acne with a call for pharma companies to focus efforts on
MAPS Public Benefit Corporation filed a new drug application for MDMA (midomafetamine capsules) for use with psychological intervention for the
Pfizer Inc. expects to close its $43 billion acquisition of Seagen Inc., on December 14, 2023. Pfizer Inc. has cleared
While hurdles remain, home healthcare could deliver better patient-centered cancer care—providing improved outcomes, enhanced quality of life, and reduced strain
The deal includes Icosavax’s lead investigational candidate, IVX-A12, a potential first-in-class vaccine being developed for both respiratory syncytial virus and
Unprecedented policy and access issues threaten R&D momentum. In the 30 years that I have been writing about FDA policy
There’s reason to believe that a positive pivot may be in the offing. The XBI, as of late last month,
Trial of Keytruda (pembrolizumab) plus chemotherapy and maintenance Lynparza (olaparib; AstraZeneca, MSD) for the treatment of metastatic squamous non-small cell
Pharm Exec: In conjunction with Bimzelx, Bimzelx Navigate can be utilized as a “personalized patient support system.” How is it
PREPVACC study expected to stop further HIV vaccination attempts after previously enrolling 1,500 participants in East and Southern Africa. PrEPVacc
Pharma companies must embrace the future to advance commercialization. Over the course of my career, I have seen significant changes
Farbman discusses the struggles that pharma companies are facing when trying to raise funds and how this is impacting IPOs.
FDA approval of bluebird bio’s Lyfgenia and Vertex Pharmaceuticals’ and CRISPR Therapeutics’ Casgevy marks significant milestone in the treatment of
Migraine with comorbid obesity have been found to cause high levels of disability and are both more common in female
Arthritis, asthma, cancer, cardiovascular diseases, chronic kidney disease, COPD, depression, and diabetes reach the highest recorded levels since the America’s
Experts from Hootsuite noted that the primary social media ROI concern for healthcare companies is the time and money it
UCB executive speaks on recent FDA approval of Bimzelx. In an interview with Pharm Exec associate editor Don Tracy, Camille
Patients with obesity are now able to access Zepbound (tirzepatide) with a prescription at retail and mail-order pharmacies across six
Jennifer Breheny Wallace, award-winning journalist and author, notes that C-Suite leaders should understand the financial risks of not taking action
New research reveals significant insurance gaps among both publicly insured and commercially insured children. In a study published last month
Pharma industry stakeholders must develop actionable roadmaps to prioritize the areas in which the use of generative artificial intelligence can
Published on: December 1, 2023 Komodo Health Insight into the complete patient journey not only offers new ways to empower field
FDA to expedite review of zotatifin plus Faslodex (fulvestrant) and Verzenio (abemaciclib) as a second- or third-line treatment for patients
The FDA previously granted accelerated approval to the Keytruda plus Padcev combination for the treatment of patients with locally advanced
Artificial intelligence is making it quicker to get drug candidates to the clinic, but it isn’t addressing the fundamental need
How to build a loyal audience of brand evangelists. Today, more than 50% of U.S. adults rely on social media
Findings show that a considerable number of adults remain uneducated on how herpes zoster is triggered. Data from a recent
Blenrep significantly extended the time to disease progression or death against existing care methods as a second-line treatment for relapsed
The use of real-world evidence can prevent pharma companies from performing studies based on flawed data. In recent years, the
Vivos becomes the first company to bring to market an alternative to continuous positive airway pressure (CPAP) or surgical neurostimulation
KarXT (xanomeline-trospium) is currently in development to treat schizophrenia and psychosis related to Alzheimer disease. The FDA has accepted a
Researchers highlight steps to be taken in the European Union to manage the challenge of ongoing drug shortages. When it
Law aims to mitigate ongoing global drug shortages. US President Joe Biden has announced approximately 30 new actions aimed at
Trial results expected to accelerate the potential of Dupixent to become the first FDA-approved treatment for chronic obstructive pulmonary disease.
Kimberlee Heidmann serves as Executive Vice President of Patient Experience and Customer Success as well as the Global Head of
Heliyon study evaluates online information, labeling accuracy, and quantitative analysis of high peroxide content gels. Since their introduction in the
Shields discusses Ferring’s recent $5 million endowment to the American Society of Reproductive Medicine. Ferring Pharmaceuticals recently announced a $5
Study emphasizes role in bridging research and development and commercial/marketing functions. According to a study published in Springer Link, the
Leuchter discusses FDA’s new pilot program. The FDA recently launched a new pilot program to encourage the development of new
Ho discusses how gamma-delta T cells can improve cancer treatments. Pharmaceutical Executive: Can you provide some background on gamma-delta T-Cells?
Medication focuses on the acute treatment of migraines. AbbVie announced results published in The Lancet evaluating the efficacy, safety, and
Smalley discusses her work with proactive signal detection. Pharmaceutical Executive: Can you describe your work with signal detection? Elizabeth Smalley:
IQVIA report explores why these shortages are increasing, and how they can be mitigated. Drug shortages are an issue that
Leuchter discusses FDA’s new pilot program. The FDA recently launched a new pilot program to encourage the development of new
Study aims to find ways industry gets involved in the most influential clinical trials, and how transparent these trials are.
Cake Delta 8 Disposable The Cake Delta 8 Disposable features a sleek new style battery designed for the perfect draw.